Control
Feb 9 2022 |
et al., Critical Care Medicine, doi:10.1097/CCM.0000000000005493 | CytoSorb Rescue for COVID-19 Patients With Vasoplegic Shock and Multiple Organ Failure: A Prospective, Open-Label, Randomized Controlled Pilot Study |
| 9% lower mortality (p=0.79). RCT 49 COVID-19 patients with vasoplegic shock and multiple organ failure showing no significant difference in shock resolution or mortality with CytoSorb extracorporeal cytokine adsorption compared to standard care. | ||
Jul 31 2021 |
et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00177-6 | Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial |
| 250% higher mortality (p=0.002). RCT 34 severe COVID-19 patients requiring extracorporeal membrane oxygenation (ECMO) showing significantly higher mortality with cytokine adsorption therapy. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.